^
    1d
    Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study (clinicaltrials.gov)
    P3, N=486, Recruiting, NRG Oncology | Not yet recruiting --> Recruiting | Initiation date: Aug 2025 --> May 2026
    Enrollment open • Trial initiation date
    |
    cisplatin • gemcitabine • Jelmyto (mitomycin urothelial gel) • fluorouracil topical
    6d
    EA2183: Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body (clinicaltrials.gov)
    P3, N=314, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD4 (CD4 Molecule)
    |
    HER-2 negative
    |
    capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical
    11d
    Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, City of Hope Medical Center
    New P1 trial
    |
    CD4 (CD4 Molecule)
    |
    irinotecan • leucovorin calcium • Yidafan (ivonescimab) • fluorouracil topical • muzastotug (ADG126)
    12d
    EAY191-A6: Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> May 2026 | Trial primary completion date: Jan 2026 --> May 2026
    Trial completion date • Trial primary completion date
    |
    MAPK1 (Mitogen-activated protein kinase 1)
    |
    BRAF V600E • BRAF V600
    |
    Mektovi (binimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical
    12d
    Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2029 --> Sep 2031 | Trial primary completion date: Sep 2029 --> Sep 2031
    Trial completion date • Trial primary completion date
    |
    IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • capecitabine • Jelmyto (mitomycin urothelial gel) • fluorouracil topical • ABP 206 (nivolumab biosimilar)
    20d
    Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=56, Recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    oxaliplatin • irinotecan • Yutuo (zimberelimab) • leucovorin calcium • fluorouracil topical • quemliclustat (AB680)
    22d
    Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=35, Not yet recruiting, Roswell Park Cancer Institute | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    |
    oxaliplatin • irinotecan • leucovorin calcium • fluorouracil topical
    29d
    Topical 5-Fluorouracil Effervescent Powder in the Treatment of Vitiligo (clinicaltrials.gov)
    P4, N=60, Recruiting, Al-Azhar University | Trial completion date: Oct 2024 --> Dec 2025 | Trial primary completion date: Oct 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    fluorouracil topical
    1m
    ATOMIC: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (clinicaltrials.gov)
    P3, N=712, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2028 --> Dec 2026 | Trial primary completion date: Jan 2028 --> Feb 2025
    Trial completion date • Trial primary completion date • Mismatch repair • Tumor mutational burden
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • CD4 (CD4 Molecule)
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • oxaliplatin • leucovorin calcium • fluorouracil topical
    1m
    Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis (clinicaltrials.gov)
    P1, N=15, Recruiting, Mayo Clinic | Trial completion date: Jan 2026 --> Apr 2030 | Trial primary completion date: Jan 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • oxaliplatin • leucovorin calcium • Proleukin (aldesleukin) • fluorouracil topical • ABP 206 (nivolumab biosimilar)
    1m
    NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=42, Active, not recruiting, OHSU Knight Cancer Institute | N=60 --> 42
    Enrollment change
    |
    gemcitabine • capecitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • fluorouracil topical
    2ms
    Topical 5-Fluorouracil (5FU) Plus Calcipotriol in Children With Palmoplantar Wart (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Mazandaran University of Medical Sciences | Not yet recruiting --> Recruiting | Trial completion date: Oct 2025 --> Aug 2026 | Trial primary completion date: Oct 2025 --> Jul 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    fluorouracil topical